Question Does stereotactic body radiation therapy (SBRT) prior to systemic therapy improve overall survival compared with systemic therapy alone in patients with locally advanced hepatocellular carcinoma (HCC)?
Findings This phase 3 randomized clinical trial found that the use of SBRT prior to sorafenib was associated with clinically important but not statistically significant improved overall survival in patients with locally advanced HCC (75% with macrovascular invasion) compared with sorafenib alone.
Meaning SBRT should be considered for selected patients with locally advanced HCC.
https://jamanetwork.com/journals/jamaoncology/article-abstract/2827892
2 Medical News 